JONES WILLIAM A JR — SEC insider filings
SEC reporting owner CIK 1373097. 18 insider filings on record with FilingPulse; latest filed 2026-09-03.
Transaction summary — filings shown
Covers all 18 filings on record, filed 2020-11-04 to 2026-09-03. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 3 legs across 1 filing — 30,000 shares, $2,286,676 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 50.
- Largest priced transaction: sale of 24,690 shares @ $76.02 ($1,876,872) in Biohaven Pharmaceutical Holding Co Ltd., filed 2020-11-04.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Biohaven Pharmaceutical Holding Co Ltd. (BHVN) | CCO-Migraine & Common Disease | 6 | — | 3 legs · 30,000 sh · $2,286,676 | 33 |
| Apogee Therapeutics, Inc. (APGE) | Director | 4 | — | — | 7 |
| Annexon, Inc. (ANNX) | Director | 3 | — | — | 3 |
| Apnimed, Inc. (APMD) | Director | 1 | — | — | 3 |
| Akili, Inc. (AKLI) | Director | 2 | — | — | 2 |
| NewAmsterdam Pharma Co N.V. (NAMS) | Chief Commercial Officer | 2 | — | — | 2 |
Insider filings — JONES WILLIAM A JR
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-03 | 4 | Apogee Therapeutics, Inc. (APGE) | Disposition to issuer (D): 34,824 · Disposition to issuer (D): 10,370 (derivative) · Disposition to issuer (D): 14,461 (derivative) · Disposition to issuer (D): 7,657 (derivative) | EDGAR |
| 2026-08-03 | 4 | Apnimed, Inc. (APMD) | Grant/award (A): 44,477 (derivative) @ $0 · Disposition to issuer (D): 44,477 (derivative) @ $0 · Grant/award (A): 44,477 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Annexon, Inc. (ANNX) | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Apogee Therapeutics, Inc. (APGE) | Grant/award (A): 7,657 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Apogee Therapeutics, Inc. (APGE) | Grant/award (A): 14,461 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Annexon, Inc. (ANNX) | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2025-01-10 | 4 | Annexon, Inc. (ANNX) | Grant/award (A): 88,000 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Grant/award (A): 43,000 | EDGAR |
| 2025-01-06 | 4 | NewAmsterdam Pharma Co N.V. (NAMS) | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Apogee Therapeutics, Inc. (APGE) | Grant/award (A): 10,370 (derivative) @ $0 | EDGAR |
| 2023-05-04 | 4 | Akili, Inc. (AKLI) | Grant/award (A): 22,000 (derivative) @ $0 | EDGAR |
| 2022-11-04 | 4 | Akili, Inc. (AKLI) | Grant/award (A): 44,000 (derivative) @ $0 | EDGAR |
| 2022-10-03 | 4 | Biohaven Pharmaceutical Holding Co Ltd. (BHVN) | Disposition to issuer (D): 14,226 @ $148.50 · Disposition to issuer (D): 11,250 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 3,000 (derivative) · Disposition to issuer (D): 775 (derivative) · Disposition to issuer (D): 29,225 (derivative) · +6 more | EDGAR |
| 2022-01-07 | 4 | Biohaven Pharmaceutical Holding Co Ltd. (BHVN) | Option exercise (M): 5,000 @ $0 · Tax withholding (F): 2,230 @ $123.86 · Option exercise (M): 3,750 @ $0 · Tax withholding (F): 1,631 @ $128.87 · Option exercise (M): 5,000 (derivative) @ $0 · Grant/award (A): 30,000 (derivative) @ $0 · +2 more | EDGAR |
| 2021-11-26 | 4 | Biohaven Pharmaceutical Holding Co Ltd. (BHVN) | Option exercise (M): 3,000 @ $0 · Tax withholding (F): 1,305 @ $115.55 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2021-01-08 | 4 | Biohaven Pharmaceutical Holding Co Ltd. (BHVN) | Option exercise (M): 5,000 @ $0 · Tax withholding (F): 2,124 @ $83.38 · Grant/award (A): 40,000 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2020-11-27 | 4 | Biohaven Pharmaceutical Holding Co Ltd. (BHVN) | Option exercise (M): 3,000 @ $0 · Tax withholding (F): 1,245 @ $90.14 · Option exercise (M): 3,000 (derivative) @ $0 | EDGAR |
| 2020-11-04 | 4 | Biohaven Pharmaceutical Holding Co Ltd. (BHVN) | Option exercise (M): 30,000 @ $50.72 · Sale (S): 24,690 @ $76.02 · Sale (S): 4,010 @ $77.01 · Sale (S): 1,300 @ $77.70 · Option exercise (M): 30,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-29 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1373097 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs